Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Budesonide Reduces eGFR Decline, Effect Could Prevent Clinical Events in IgA Nephropathy
November 4th 2023Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.
Read More
Phase 2b Data, Phase 3 Trial Design Provide New Insight into Atacicept in IgAN
November 4th 2023Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.
Read More
Sparsentan Use Could Lower Risk of Kidney Failure, Death in FSGS
November 3rd 2023Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.
Read More
Urate-Lowering Therapy Could Also Lower Blood Pressure in Gout Patients
November 2nd 2023An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.
Read More
FIDELITY Analysis Details Benefits of Early Albuminuria Reduction in CKD
November 2nd 2023Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.
Read More
ENVISION Trial: Sibeprenlimab Reduces 24-Hour UACR in IgA Nephropathy
November 2nd 2023Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.
Read More
Functional Impairment Increases Depression Risk in Psoriasis, Psoriatic Arthritis
October 26th 2023A cross-sectional study of survey data shows more than 50% of psoriasis and over 60% of psoriatic arthritis patients have depressive symptoms, with results drawing a link between functional impairment and the likelihood of depressive symptoms.
Read More
FDA Approves First Subcutaneous Infliximab for Maintenance Therapy in UC and Crohn Disease
October 23rd 2023The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.
Read More